- Histrelin Acetate
-
-
2026-09-11
- CAS:76712-82-8
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
- Histrelin
-
- $15.00
-
2021-07-02
- CAS:76712-82-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Histrelin
-
- $7.00
-
2019-09-02
- CAS:76712-82-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1000KG
|
| Product Name: | Histrelin | | Synonyms: | N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)-1-pyrrolidinyl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-[1-(phenylmethyl)-4-imidazoly;1-9-LUTEINIZING HORMONE-RELEASING FACTOR (SWINE), 6-[1-(PHENYLMETHYL)-D-HISTIDINE]-9-(N-ETHYL-L-PROLINAMIDE)-;Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt acetate salt;5-oxo-L-pmlyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N^^-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-pmlinamide;RWJ-17070;Supprelin;5-Oxo-L-Pro-L-His-L-Trp-L-Ser-L-Tyr-1-benzyl-D-His-L-Leu-L-Arg-L-Pro-N-ethyl-NH2;Histreline Acetate | | CAS: | 76712-82-8 | | MF: | C66H86N18O12 | | MW: | 1323.53 | | EINECS: | | | Product Categories: | hormones;Peptide | | Mol File: | 76712-82-8.mol |  |
| | Histrelin Chemical Properties |
| alpha | D20 -33.9° (c = 1 in acetic acid) | | density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Aqueous Acid (Slightly), DMSO (Slightly), Methanol (Slightly) | | form | powder | | pka | 9.82±0.15(Predicted) | | Sequence | {Pyr}-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt | | Stability: | Hygroscopic | | InChIKey | HHXHVIJIIXKSOE-HMGGNIPDNA-N |
| Hazard Codes | T | | Risk Statements | 60 | | Safety Statements | 53-22-36/37/39-45 | | WGK Germany | 3 | | RTECS | OK6370800 | | HS Code | 3504009000 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Repr. 1B | | Hazardous Substances Data | 76712-82-8(Hazardous Substances Data) |
| | Histrelin Usage And Synthesis |
| Description | Histrelin, a synthetic gonadotrophin-releasing hormone (GnRH) agonist, was introduced
as a first-line therapy for the treatment of central precocious puberty. When administered over
a prolonged period, it suppresses the release of gonadotrophin, inhibits ovarian and testicular
steroidogenesis, and prevents sexual maturation. Superior to the traditional therapy with
progestational agents, histrelin appears to have decelerating effects on skeletal maturation
allowing more statural growth and significantly increased final adult height. Histrelin has also
been used to treat other disorders including endometriosis, polycystic ovarian disease,
uterine leiomyomas, severe premenstrual syndrome and to prevent acute intermittent
porphyria. | | Chemical Properties | [α]D20-33.9°(C=1, acetic acid). | | Originator | Johnson & Johnson (U.S.A.) | | Uses | LHRH agonist. | | Uses | [des-Gly10, D-His(Bzl)6]-LH-RH ethylamide has been used:
- for inducing Batrachoseps gravid females to oviposit
- for comparing the effect of LHRH (luteinizing hormone-releasing hormone) agonists and dopamine antagonists in Lithobates pipiens
- for inducing oviposition in females of Taricha granulosa and Ensatina eschscoltzii
- to induce spawning in Spea hammondii adults
| | Definition | ChEBI: An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotro
in-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. | | Brand name | Supprelin (Roberts Pharmaceutical). | | Biochem/physiol Actions | Glp-His-Trp-Ser-Tyr-His(Bzl)-Leu-Arg-Pro-NHEt ([des-Gly10, D-His(Bzl)6]-LH-RH) is a GnRH (gonadotropin-releasing hormone) agonist, histerelin. GnRH (Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), which is also referred as LHRH (luteinizing hormone-releasing hormone) or gonadorelin, is crucial for mammalian reproduction and is released from hypothalamic neurons. It is responsible for the secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), from the pituitary glands. Mutations in GnRH are associated with normosmic congenital hypogonadotropic hypogonadism. Histerelin is used for the treatment of central precocious puberty in children. It inhibits actions of sex steroids on the male and female reproductive organs. | | Description | Histrelin has a molecular formula of C66H86N18O12, a.a. sequence of Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt and having a Mw of 1323.32 Dalton. | | Background | Histrelin is a hormone similar to one normally released from the hypothalamus gland in the brain. Histrelin works by decreasing the amount of estrogen and testosterone in the blood. Suppressing estrogen can cause thinning of the bones or slowing of their growth. Histrelin acetate is a potent LHRH agonist which stimulates LH and FSH release and inhibits the actions of sex steroids on the male and female reproductive tracts. After a transient increase, continuous administration results in down regulation of LH and FSH levels followed by a suppression of ovarian and testicular steroid biosynthesis. Histrelin potency in vivo and in vitro is similar to that of the D-Trp6-containing analog. Especially because of its high water solubility and greater lipophilic character, it appears promising for clinical application. |
| | Histrelin Preparation Products And Raw materials |
|